期刊文献+

曲美他嗪对高血压心脏病患者治疗作用观察 被引量:8

Therapeutic Value of Trimetazidine in Patients with Hypertensive Heart Disease
暂未订购
导出
摘要 目的研究曲美他嗪对高血压心脏病患者的治疗作用。方法入选2006年4月至2008年11月在德阳市人民医院诊断为高血压心脏病患者84例。以入院顺序单双号法随机分为常规治疗组(对照组)和加用曲美他嗪组,每组各42例,超声心动图检查并记录入选时及治疗12、24个月时左室射血分数(LVEF)及左心室质量指数(LVMI)。结果 12个月时,曲美他嗪组患者LVEF较入选时明显增加(P=0.0389),24个月时进一步改善(P=0.0093)。对照组患者LVEF于12、24个月时略增加,但差异无统计学意义(P=0.5426)。12、24个月时LVMI于对照组有降低趋势,但均无统计学意义。12个月时曲美他嗪组LVMI明显减低(P=0.0421),24个月时减低更明显(P=0.0086)。两组间比较,12个月时曲美他嗪组LVEF明显高于对照组(P=0.0443),24个月时差异更显著(P=0.0085);12个月时曲美他嗪组LVMI低于对照组(P=0.0392),24个月时差异更明显(P=0.0053)。结论在常规降压治疗的基础上加用曲美他嗪,有助于进一步改善左心室收缩功能及逆转左心室肥厚。 Objective To study the effects of trimetazidine on the left ventricular function of patients with hypertensive heart disease(HHD).Methods 84 patients with HHD were enrolled in the people's hospital of Deyang from April 2006 to November 2008.They were randomly assigned to either conventional treatment group(control group) or trimetazidine in addition to conventional treatment group(trimetazidine group),42 patients per group.Left ventricular ejection fraction(LVEF) and left ventricular mass index(LVMI)were determined by echocardiography at baseline and 12,24 months after treatment.Results Compared with baseline,LVEF in trimetazidine group increased significantly at 12 months(P=0.0389) and increased more notably at 24 months(P=0.0093).The increment of LVEF in control group was not statistically significant at 12 and 24 months(P=0.5426).Compared with baseline,LVMI in control group was lightly decreased but was not significant at 12 and 24 months,LVMI in trimetazidine group was significantly decreased at 12 months(P=0.0421) and more markedly decreased at 24 months(P=0.0086).The increment of LVEF in trimetazidine group was significantly higher than that in control group at 12 months(P=0.0443) and the difference was more notable at 24 months(P=0.0085).The decrease of LVMI between the two groups was significant at 12 months(P=0.0392) and more marked at 24 months(P=0.0053).Conclusions Trimetazidine in addition to conventional therapy was associated with the significant improvement of left ventricular function and the reversal of left ventricular hypertrophy.
出处 《中国医药指南》 2011年第13期201-203,共3页 Guide of China Medicine
关键词 曲美他嗪 高血压 心室功能 Ttrimetazidine Hypertension Ventricular function Left
  • 相关文献

参考文献4

二级参考文献20

  • 1Wiemer M, Langer C, Kottmann T, et al. Outcome in the elderly undergoing percutaneous coronary intervention with sirolimus-eluting stents: results from the prospective multicenter German Cypher Stent Registry. Am Heart J, 2007,154:682-687.
  • 2Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Pharmacol, 1994,37:279-288.
  • 3Rosano GM, Vitale C, Sposato B, et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo- controlled study. Cardiovasc Diabetol, 2003,2 : 16.
  • 4Fragasso G, Piatti Md PM, Monti L, et al. Short and long term beneficial effects of trimetazidine in patients with diabetes and ischemic eardiomyopathy. Am Heart J, 2003,146:18.
  • 5Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography : American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of two-dimensional eEchocardiograms. J Am Soc Echocardiogr, 1989,2: 358-367.
  • 6Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme a thiolase. Circ Res, 2000,86..580-588.
  • 7Renaud JF. Internal pH, Na^+ and Ca^2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovase Drugs Ther, 1988,1:677-686.
  • 8Brottier L, Baart JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J, 1990,11 : 207- 212.
  • 9Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy, gur Heart J, 2001,22:2164-2170.
  • 10Mandinov L, Eberli FR, Seiler C, et al. Diastolic heart failure. Cardiovasc Res, 2000,45:813-825.

共引文献86

同被引文献40

  • 1梁叶青,邓大宏,严健渝.曲美他嗪改善老年缺血性心肌病患者左室功能疗效观察[J].中国医师进修杂志,2006,29(1):59-59. 被引量:9
  • 2李静芝,王永义.曲美他嗪对老年心肌梗塞后左室功能不全康复的研究[J].心血管康复医学杂志,2006,15(2):140-142. 被引量:1
  • 3王玮玮.曲美他嗪治疗慢性充血性心力衰竭80例疗效观察[J].中国杜区医师医学专业半月刊,2009,11(16):38.
  • 4Dahlof B,Devereux R B,Kjeldsen SE,et al.Cardiovascularmorbidity and mortality in the Losartan Intervention ForEndpoint reduction in hypertension study(LIFE):a randomizedtrial against atenolool[J].Lancet,2002,359(9311):995-1003.
  • 5Mohammed AA, Januzzi J L Jr. Natriuretic peptidos in the diagnosis and management of acute heart failure [J]. Heart Fail Clin, 2009,5(4) :489-500.
  • 6Bittner V, Weiner D, Yusuf S, et al. Prediction of mortality and morbidity with 6-minute walk test in patients with left ventricular dysfunction [J]. JAMA, 1993,270(14): 1 702-1 707.
  • 7Ferrari R, Cicchitelli G, Merli E, et al. Metabolic modulation and optimization of energy consumption in heart failure [J]. Med Clin North Am,2003,87(2):493-507.
  • 8Lu C,Dabrowski P,Fragasso G,et al.Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease[].The American Journal of Cardiology.1998
  • 9Mohand-Said S,Jacquet A,Lucien A,et al.Protective effect of trimetazi-dine in a model of ischemia-reerfusion in the rat retina[]..2002
  • 10无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3756

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部